Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 22;17(9):1248.
doi: 10.3390/ph17091248.

Effects, Doses, and Applicability of Gestrinone in Estrogen-Dependent Conditions and Post-Menopausal Women

Guilherme Renke  1 , Mariana Antunes  1 , Renato Sakata  1 , Francisco Tostes  1
Affiliations

Effects, Doses, and Applicability of Gestrinone in Estrogen-Dependent Conditions and Post-Menopausal Women

Guilherme Renke et al. Pharmaceuticals (Basel). .

Abstract

Gestrinone (R-2323), or ethylnorgestrienone, is a synthetic steroid of the 19-nortestosterone group more commonly used as an oral, intravaginal, or subcutaneous implant for the treatment of endometriosis, contraception, and estrogen-dependent conditions such as hypermenorrhea, premenstrual dysphoria, and intense menstrual cramps. This review aims to reevaluate the routes, doses, and applicability proposed for using gestrinone, including its use in new conditions such as menopause, lipedema, and sarcopenia. Here, we present the possible application of gestrinone as a long-acting therapeutic possibility through hormonal implants and the benefits and potential risks. Available evidence on the safety of doses and routes is limited. Gestrinone appears to be effective compared to other progestins and may have some advantages in the treatment of estrogen-dependent pathologies. Future research must evaluate gestrinone's long-term safety and potential therapeutic indications.

Keywords: endometriosis; gestrinone; hormone replacement therapy; implant; menopause.

PubMed Disclaimer

Conflict of interest statement

G.R. is a research physician at ELMECO Hormonal Implants. All other authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
Future therapeutic possibilities of using gestrinone implants in estrogen-dependent pathologies and menopause.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Coutinho E.M., Da Silva A.R. Contraceptive effectiveness of Silastic implants containing the progestin R-2323. Contraception. 1975;11:625–635. doi: 10.1016/0010-7824(75)90059-1. - DOI - PubMed
    1. Schindler A.E., Campagnoli C. Classification and pharmacology of progestins. Maturitas. 2008;61:171–180. doi: 10.1016/j.maturitas.2008.11.013. - DOI - PubMed
    1. Słopień R., Męczekalski B. Aromatase inhibitors in the treatment of endometriosis. Menopausal Rev. 2016;1:43–47. doi: 10.5114/pm.2016.58773. - DOI - PMC - PubMed
    1. Coutinho E.M., Azadian-Boulanger G. Treatment of fibrocystic disease of the breast with gestrinone, a new trienic synthetic steroid with anti-estrogen, anti-progesterone properties. Int. J. Gynecol. Obstet. 1984;22:363–366. doi: 10.1016/0020-7292(84)90067-5. - DOI - PubMed
    1. Ciou H.H., Lee T.H. Repurposing gestrinone for tumor suppressor through P21 reduction regulated by JNK in gynecological cancer. Transl. Res. 2022;243:21–32. doi: 10.1016/j.trsl.2021.12.002. - DOI - PubMed

Grants and funding

LinkOut - more resources